MedTrace Logo

European Study of Cerebral Aspergillosis Treated With Isavuconazole

NCT04486885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2025-04-30

No results posted yet for this study

Summary

Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile.

The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.

Conditions

  • Cerebral Aspergillosis
  • Invasive Aspergillosis

Sponsors & Collaborators

  • Imagine Institute

    lead OTHER

Principal Investigators

  • Fanny Lanternier, MD · Hôpital Necker

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-08-01
Completion
2023-03-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04486885 on ClinicalTrials.gov